InflaRx (IFRX) Other Non-Current Liabilities (2016 - 2026)
InflaRx's (IFRX) quarterly Other Non-Current Liabilities came in at $33932.9 in Q1 2026, down 30.32% year-on-year from $48697.0 in Q1 2025, and down 91.88% quarter-over-quarter from $417838.1 in Q4 2025.
InflaRx (IFRX) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
InflaRx has disclosed Other Non-Current Liabilities across 11 years of filings, most recently posting $33932.9 for Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $33932.9, down 30.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $33932.9 (down 30.32% YoY), and the FY2025 annual result was $417838.1, up 960.33% from the prior year.
- Other Non-Current Liabilities came in at $33932.9 for Q1 2026 at InflaRx, down from $417838.1 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.1 million in Q3 2023 to a low of -$2.9 million in Q2 2024.
- The 5-year median for Other Non-Current Liabilities is $39406.6 (2024), against an average of $103777.2.
- Across the five-year window, Other Non-Current Liabilities soared 61625.86% in 2023 and plunged 4536.37% in 2024, its largest moves.
- InflaRx's Other Non-Current Liabilities stood at $9593.4 in 2022, then surged by 30609.7% to $2.9 million in 2023, then plunged by 98.66% to $39406.6 in 2024, then jumped by 960.33% to $417838.1 in 2025, then slumped by 91.88% to $33932.9 in 2026.
- The last three Other Non-Current Liabilities figures came in at $33932.9 (Q1 2026), $417838.1 (Q4 2025), and $399353.9 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,932.89 |
| Dec 31, 2025 | 417,838.08 |
| Sep 30, 2025 | 399,353.90 |
| Jun 30, 2025 | 409,331.34 |
| Mar 31, 2025 | 48,696.99 |
| Dec 31, 2024 | 39,406.59 |
| Sep 30, 2024 | -2.91 Mn |
| Jun 30, 2024 | -2.92 Mn |
| Mar 31, 2024 | 67,807.44 |
| Dec 31, 2023 | 2.95 Mn |
| Sep 30, 2023 | 3.15 Mn |
| Jun 30, 2023 | 65,817.86 |
| Mar 31, 2023 | 17,158.44 |
| Dec 31, 2022 | 9,593.39 |
| Sep 30, 2022 | 5,102.88 |
| Jun 30, 2022 | -8,396.67 |
| Mar 31, 2022 | -7,681.28 |
| Dec 31, 2021 | 22,722.70 |
| Sep 30, 2021 | 14,304.76 |
| Jun 30, 2021 | -8,453.99 |